by investar » Wed May 08, 2019 4:28 am
9 new systems installed.
Recent Financial Highlights and Business Accomplishments:
Revenue totaled $3.0 million during the first quarter of 2019, including sale and installation of nine CorPath GRX Systems;
Recorded purchase orders for 11 CorPath GRX Systems, an increase of 83% compared to purchase orders received in Q4 2018 and 267% growth compared to the purchase orders received in Q1 2018;
Sold 602 single-use cassettes in the quarter, generating revenue of nearly $0.3 million;
Completed the first-ever clinical robotic-assisted percutaneous coronary intervention (PCI) procedures in Japan in partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital, marking initial enrollment in a post-market study of CorPath GRX;
Received CE mark for a neurovascular indication, allowing the Company to sell neurovascular robots in 33 countries that accept CE mark;
Received an order for the first CorPath GRX System in Italy;
Continued advancement of co-development and co-commercialization partnership discussions to advance the neurovascular robotic platform with remote capabilities; and
Raised approximately $19.8 million in gross proceeds in a private placement sale of unregistered Corindus shares to a large institutional investor and existing investors (Hudson Executive Capital and BioStar Ventures):